Drugs / SY-005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04217629 | Apr → Oct 2019 | infectious disease with sepsis | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04898322 | Jan 2022 → Jul 2023 | infectious disease with sepsis | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04898322 ↗ |
| Known as | recombinant human annexin A5 | “This Phase IIa Randomized, Double-blind, Parallel Group, Placebo-controlled, multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple...” NCT04898322 ↗1“This is a randomized, double-blind, placebo-controlled, dosed tolerability, pharmacokinetic study of a single-dose/multiple-doses incremental intravenous injection of...” NCT04217629 ↗ |
| Modality | Protein / enzyme biologic | “SY-005 （Recombinant Human Annexin A5）” NCT04217629 ↗ |
| Route | Intravenous | “single-dose/multiple-doses incremental intravenous injection” NCT04217629 ↗ |